VIRUSTA

Serial Number 90528941
602

Registration Progress

Application Filed
Feb 15, 2021
Under Examination
Approved for Publication
Published for Opposition
Registered

Re-Apply for This Trademark

This trademark is no longer active. You may be able to file a new application for the same or similar mark.
Mark: VIRUSTA
Previous Owner: Ola Mana, LLC
Classes: 005

Trademark Image

VIRUSTA

Basic Information

Serial Number
90528941
Filing Date
February 15, 2021
Abandonment Date
March 22, 2022
Drawing Code
4000

Status Summary

Current Status
Inactive
Status Code
602
Status Date
Apr 11, 2022
Classes
005

Rights Holder

Ola Mana, LLC

16
Address
C/O HPS Law Group
123 N Centennial Way Ste 205
Mesa, AZ 85201

Ownership History

Ola Mana, LLC

Original Applicant
16
Mesa, AZ

Legal Representation

Attorney
Burt Skiba

USPTO Deadlines

No Upcoming Deadlines

No upcoming deadlines found for this trademark.

Application History

13 events
Date Code Type Description Documents
Oct 6, 2022 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Oct 6, 2022 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Oct 6, 2022 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Apr 11, 2022 MAB2 E ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND Loading...
Apr 11, 2022 MAB2 O ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND Loading...
Apr 11, 2022 ABN2 O ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE Loading...
Sep 21, 2021 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Sep 21, 2021 GNRT F NON-FINAL ACTION E-MAILED Loading...
Sep 21, 2021 CNRT R NON-FINAL ACTION WRITTEN Loading...
Sep 21, 2021 RFTP Z REMOVED FROM TEAS PLUS Loading...
Sep 7, 2021 DOCK D ASSIGNED TO EXAMINER Loading...
May 18, 2021 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Feb 18, 2021 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Nasal spray preparations; Nasal and oral spray preparations for use as central nervous system stimulants; Pharmaceutical preparations for the treatment and prevention of COVID-19 as a immune response booster in viral and bacterial infections in form of a nasal spray reduction of inflammatory cytokines for balanced immune response; Pharmaceutical preparations for COVID-19 as a immune response booster in viral and bacterial infections in the form of a nasal spray reduction of inflammatory cytokines for balanced immune response; Decongestant nasal sprays; Drug delivery agents in the form of a nasal spray for COVID-19 as a immune response booster in viral and bacterial infections that facilitate the delivery of pharmaceutical preparations
First Use Anywhere: 0
First Use in Commerce: 0

Classification

International Classes
005